Loading...
XHKG
6667
Market cap207mUSD
Mar 31, Last price  
7.20HKD
Name

Mega Genomics Ltd

Chart & Performance

D1W1MN
XHKG:6667 chart
P/E
48.83
P/S
9.69
EPS
0.13
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
151m
+3.82%
123,700,000203,220,000237,185,000145,727,000151,300,000
Net income
30m
P
29,691,00079,097,00079,015,000-17,618,00030,038,000
CFO
164m
P
37,272,000102,836,00030,629,000-6,911,000163,684,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services comprising ApoE gene testing package that assesses the lipid metabolism capacity and the risk for various related diseases, including Alzheimer's disease; folate metabolic capacity assessment, which analyzes genes related to folate metabolism capacity to determine the risk of developing hyperhomocysteinemia, cardiovascular, and cerebrovascular diseases; Parkinson's disease risk assessment; full-scale cancer risk assessment package; and cardiovascular and cerebrovascular disease risk assessment package. The company also provides advanced testing services, which include Hereditary breast cancer/ovarian cancer genetic testing, Septin9 colorectal cancer screening test, and RNF180/Septin9 gastric cancer screening test; and executive testing services, such as personal whole genome test and whole-exome sequencing package for adults. It offers testing services through self-developed laboratory-developed tests and In-vitro diagnostics testing kits. The company serves health checkup centers, hospitals, and various other customers. Mega Genomics Limited was founded in 2016 and is based in Beijing, China.
IPO date
Jun 22, 2022
Employees
267
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT